Solid Biosciences up on FDA's 'orphan' tag for Duchenne gene therapy

Solid Biosciences

16/01/2024 13:27

** Solid Biosciences' shares  SLDB.O  up 7.1% to $8.30
premarket
    ** Drug developer reports U.S. FDA granted orphan drug
designation to its gene therapy candidate SGT-003 for treatment
of Duchenne Muscular Dystrophy (DMD), a progressive
muscle-wasting disorder 
    ** Orphan drug status is given by the FDA to drugs that
treat rare conditions, and are protected through a series of
government incentives once in market 
    ** Patient dosing in the early-to-mid-stage trial is
expected to commence in mid-to-late Q1 of 2024 - company 
    ** The agency granted "fast track" designation to the
experimental therapy last year in December 
    ** Co's stock rose ~14% in 2023 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))